Finance

Lists
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
USD 12,73
+0,55%
(+0,070) 1D
USD 12,85
+0,96% (+0,12)
After hours
Closed: 19 Aug., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
USD 12,67
High
USD 13,16
Low
USD 12,63
Mkt. cap
218,33 m
Avg. vol.
518,44 k
Volume
598,84 k
52-wk high
USD 39,45
52-wk low
USD 9,40
EPS
-USD 12,92
Beta
1,69
Shares outstanding
17,15 m
No. of employees
142
Open
USD 12,67
High
USD 13,16
Low
USD 12,63
Mkt. cap
218,33 m
Avg. vol.
518,44 k
Volume
598,84 k
52-wk high
USD 39,45
52-wk low
USD 9,40
EPS
-USD 12,92
Beta
1,69
Shares outstanding
17,15 m
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, New Jersey, Verenigde State van Amerika
Sector-
Websitetonixpharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current USD 12,73
USD 65,00 (+410,60%)
Average
USD 38,00 (+198,51%)
Lowest
USD 22,00 (+72,82%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
USD 65,00
+410,6%
08/17/2026
Stacy Ku
TD Cowen
Buy
Maintained
USD 22,00
+72,8%
08/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
USD 27,00
+112,1%
08/10/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
USD 37,00
+190,7%
03/16/2026
Last report
10 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 2,47 / -USD 2,62
+5,58%beat
Revenue / Est. (USD)
13,54 m / 7,72 m
+75,38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
3,29 m
5,39 m
6,88 m
13,54 m
Cost of goods sold
1,37 m
1,06 m
1,58 m
703,00 k
Cost of revenue
1,37 m
1,06 m
1,58 m
703,00 k
Research and development expenses
9,29 m
16,94 m
18,21 m
19,42 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25,70 m
35,68 m
28,62 m
35,96 m
Operating expense
34,99 m
52,62 m
46,84 m
55,38 m
Total operating expenses
36,36 m
53,68 m
48,42 m
56,08 m
Operating income
-33,07 m
-48,29 m
-41,54 m
-42,54 m
Other non operating income
-174,00 k
32,00 k
-3,00 k
551,00 k
EBT including unusual items
-32,01 m
-46,91 m
-40,19 m
-40,55 m
EBT excluding unusual items
-32,01 m
-46,91 m
-40,19 m
-40,55 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,01 m
-46,91 m
-40,19 m
-40,55 m
Net profit margin
-972,95%
-870,32%
-584,38%
-299,41%
Earnings per share
-3,70
-3,98
-2,93
-2,47
Interest and investment income
1,23 m
1,34 m
1,35 m
1,43 m
Interest expense
-
-
-
-
Net interest expenses
1,23 m
1,34 m
1,35 m
1,43 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,61 m
-47,80 m
-40,98 m
-41,92 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme